

Special Issue

Small Molecule Inhibitors of Polymerases Involved in Human Diseases

Message from the Guest Editors

In this context, we are proposing a new Special Issue titled "Small Molecule Inhibitors of Polymerases Involved in Human Diseases". This Special Issue welcomes the submission of original research, communications, and review manuscripts focusing on polymerases as targets for therapy, novel inhibitor and drug discovery strategies, as well as structural and mechanistic characterization of relevant polymerase–inhibitor complexes for human diseases.

- DNA polymerases
- RNA polymerases
- antibiotics
- antiviral
- anticancer

Guest Editors

Dr. Francesc Xavier Ruiz

Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, New Brunswick, NJ, USA

Dr. Joy Y. Feng

Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA

Deadline for manuscript submissions

closed (31 December 2022)



Molecules

an Open Access Journal
by MDPI

Impact Factor 5.1
CiteScore 10.3
Indexed in PubMed



mdpi.com/si/92956

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 5.1
CiteScore 10.3
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).